Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

Progress in Cardiovascular Diseases

Volumn 53, Issue 2, 2010, Pages 114-120

  Cheng, Hui ^a   Force, Thomas ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardiotoxicity; Heart failure; Kinase inhibitors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AFINITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NANOPARTICLE; NILOTINIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; POLYMER; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UO 126; VOTRIENT; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPEREOSINOPHILIC SYNDROME; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHILADELPHIA 1 CHROMOSOME; PROTEIN TARGETING; SIDE EFFECT; SOLID TUMOR; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; NEOPLASMS; PATHOLOGY; PREVENTION AND CONTROL; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; NEOPLASMS; PROTEIN KINASE INHIBITORS; RISK ASSESSMENT; STRUCTURE-ACTIVITY RELATIONSHIP; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77955865478     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.06.006     Document Type: Article

References (35)

1. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
2. Manning G., Whyte D.B., Martinez R., et al. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
3. Haber D.A., Settleman J. Cancer: drivers and passengers. Nature 2007, 446:145-146.
4. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
5. Bantscheff M., Eberhard D., Abraham Y., et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007, 25:1035-1044.
6. Quintas-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848.
7. Cheng H., Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010, 106:21-34.
8. Sherbenou D.W., Druker B.J. Applying the discovery of the Philadelphia chromosome. J Clin Invest 2007, 117:2067-2074.
9. Okram B., Nagle A., Adrian F.J., et al. A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol 2006, 13:779-786.
10. Ohren J.F., Chen H., Pavlovsky A., et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004, 11:1192-1197.
11. Kerkela R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
12. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
13. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
14. Hoshijima M., Chien K.R. Mixed signals in heart failure: cancer rules. J Clin Invest 2002, 109:849-855.
15. Crone S.A., Zhao Y.Y., Fan L., et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
16. Ghoreschi K., Laurence A., O'Shea J.J. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 2009, 10:356-360.
17. Kerkela R., Woulfe K.C., Durand J.B., et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2009, 2:15-25.
18. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10:307-318.
19. Izumiya Y., Shiojima I., Sato K., et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006, 47:887-893.
20. Sano M., Minamino T., Toko H., et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
21. Khakoo A.Y. Regulation of hypertrophic responses by PDGFRβ. American Heart Association, Basic Cardiovascular Sciences annual meeting, Lake Las Vegas, NV; 2009 July 21st 2009.
22. Garcia-Echeverria C., Sellers W.R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27:5511-5526.
23. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
24. Muslin A.J., DeBosch B. Role of Akt in cardiac growth and metabolism. Novartis Found Symp 2006, 274:118-126. discussion 26-31, 52-55, 272-276.
25. McMullen J.R., Jay P.Y. PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 2007, 6:910-913.
26. Potts M.B., Vaugha A.E., McDonough H., et al. Reduced Apaf-1 levels in cardiomyocytes engage a strict regulation of apoptosis by endogenous XIAP. J Cell Biol 2005, 171:925-930.
27. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
28. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
29. Fernandez A., Sanguino A., Peng Z., et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007, 117:4044-4054.
30. Demetri G.D. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest 2007, 117:3650-3653.
31. Crespo A., Zhang X., Fernandez A. Redesigning kinase inhibitors to enhance specificity. J Med Chem 2008, 51:4890-4898.
32. Fernandez A., Crespo A., Tiwari A. Is there a case for selectively promiscuous anticancer drugs?. Drug Discov Today 2009, 14:1-5.
33. Alexis F., Pridgen E.M., Langer R., et al. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010, 55-86.
34. Basu S., Harfouche R., Soni S., et al. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Natl Acad Sci U S A 2009, 106:7957-7961.
35. Harfouche R., Basu S., Soni S., et al. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Angiogenesis 2009, 12:325-338.